CRISPR Therapeutics focuses on developing gene-based medicines using its proprietary CRISPR/Cas9 platform. The company develops gene-based medicines, a transformative part of healthcare stocks. It ...
The FDA approved the expansion of Casgevy, which had previously been greenlit for patients 12 and up, into a younger pediatric population under the agency’s Commissioner’s National Priority Voucher ...
Gene editing donor organs during machine perfusion could rescue more than 28,000 organs discarded annually in the US, per a ...
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global ...
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track ...
BOSTON, May 12, 2026 /PRNewswire/ -- GenScript Biotech Corporation announced the launch of TurboCHO™ Protein Expression Kit, a next-generation antibody expression reagent designed to set a new ...
Rudolf Virchow, a 19th-century Prussian pathologist, considered organisms a kind of “cellular democracy,” a harmonious republic of cooperating cells. Wilhelm Roux, who studied under Virchow and later ...
Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
PISCATAWAY, N.J., April 14, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced its 2025 Environmental, Social, and Governance (ESG) Report, positioning the company at the forefront of ...
Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...
Good day, and thank you for standing by. Welcome to Genscript 2025 Annual Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like ...